Clinical Trial: Cancer

Mirati-EAP-001

Full Name

Expanded Access of Adagrasib (MRTX849) in Patients with Advanced Solid Tumors Who Have a KRAS G12C Mutation

Description

The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

Eligibility

Inclusion Criteria

Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor
Confirmed presence of a KRASG12C mutation
Ineligible for an ongoing clinical trial of MRTX849
No available or not eligible for standard of care treatment
Adequate organ function
CNS Metastases (within set parameters) are allowed
ECOG performance status of ≤ 2

Exclusion Criteria

History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow
Prior therapy targeting a KRAS G12C mutation
Other active cancer

Doctor(s) Running This Study